Development of the value strategy of your products is based on an in-depth understanding of the science, an accurate knowledge of the clinical and reimbursement landscape, and an informed view on the current and future competitive environment. At Mapi, our global team with extensive EU and US HTA expertise and experience can support your strategy development from early dialog to full pricing and reimbursement process.
Mapi has extensive experience of early HTA scientific advice providing full support in over 20 early HTA scientific advice engagements for innovative products in oncology, Alzheimer’s disease, pain, and a range of rare diseases. Early HTA scientific advice supports product teams, new innovative technologies, and clinical development programs in defining and generating evidence that is relevant for HTA assessors, payers, and regulators. This includes scientific advice with regulators / HTA bodies, recommendations for real-world data generation, strategic pathway to pricing and reimbursement, and innovative contracting. In addition, we offer opportunities for services development for patients, physicians, and stakeholders, and training in market access.
Strategic Consulting services include:
- Early Integrated Scientific Advice
- Market Access Roadmaps
- HTA Policy Consulting
- Access Related Reimbursement Analysis
- HEOR Strategy and Health Economic Modelling
- Bespoke Training in Strategy and Market Access